Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.

Abstract

ABSTRACT:

We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16α-[18F]fluoro-17β-estradiol ([18F]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [18F]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [18F]-FDG PET because of physiological [18F]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [18F]-FES PET imaging. [18F]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

• Authors: Jorianne Boers, Carolina P Schröder, Geke A P Hospers, Erik F J de Vries, Andor W J M Glaudemans
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 46 Issue 3 Pg. e165-e167 (Mar 01 2021) ISSN: 1536-0229 [Electronic] United States
• PMID: 33181752 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Receptors, Estrogen
• Estradiol
• 16-fluoroestradiol

Topics

• Brain Neoplasms (secondary)
• Breast Neoplasms (diagnostic imaging, metabolism, pathology)
• Dura Mater (diagnostic imaging)
• Estradiol (analogs & derivatives)
• Female
• Humans
• Positron-Emission Tomography
• Receptors, Estrogen (metabolism)